小肠细菌过度生长对肝硬化的影响及其治疗对策

牛国超; 孙东磊; 张晓岚

doi:10.3969/j.issn.1001-5256.2022.09.038

小肠细菌过度生长对肝硬化的影响及其治疗对策

DOI: 10.3969/j.issn.1001-5256.2022.09.038

河北医科大学第二医院消化内科，石家庄 050035

基金项目:

河北省医学科学研究课题计划 (20220117);

河北省研究生创新资助项目 (CXZZBS2020112)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：牛国超负责文章撰写；孙东磊协助文章修改；张晓岚负责指导文章书写及修改。

详细信息

通信作者:
张晓岚，xiaolanzh@126.com

计量
- 文章访问数: 562
- HTML全文浏览量: 119
- PDF下载量: 40
- 被引次数: 0
出版历程
- 收稿日期: 2022-02-20
- 录用日期: 2022-04-02
- 出版日期: 2022-09-20

Influence of small intestinal bacterial overgrowth on liver cirrhosis and its treatment

Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang 050035, China

Research funding:

Medical Science Research Project of Hebei Province (20220117);

Postgraduate Innovation Funding Project of Hebei Province (CXZZBS2020112)

More Information

Corresponding author: ZHANG Xiaolan, xiaolanzh@126.com(ORCID: 0000-0002-7047-3634)

摘要

摘要: 小肠细菌过度生长(SIBO)以小肠内菌群数量或菌群种类改变为特点。肝硬化患者经常出现肠道淤血、水肿和蠕动减慢，常常发生SIBO，而SIBO又可进一步加重肠道异常。在肝硬化患者中，SIBO可导致明显的不良临床后果，由于肠道通透性增加易使细菌移位进入体循环，因此，SIBO被认为是肝硬化患者、自发性细菌性腹膜炎和肝性脑病发病机理中的重要危险因素。抗生素尤其是利福昔明是SIBO最有效的治疗方法。此外，促动力药、益生菌、非选择性β受体阻滞剂以及肝移植术等潜在治疗方法也在研究中。
- 肝硬化 /
- 小肠细菌过度生长 /
- 胃肠道微生物组 /
- 治疗学
Abstract: Small intestinal bacterial overgrowth (SIBO) is characterized by changes in the number or species of small intestinal flora. Patients with liver cirrhosis often have intestinal congestion, edema, and delayed peristalsis and develop SIBO, which can further aggravate intestinal abnormalities. In patients with liver cirrhosis, SIBO can lead to significant adverse clinical outcomes, and since the increase in intestinal permeability may cause bacterial translocation into systemic circulation, SIBO is considered an important risk factor in the pathogenesis of liver cirrhosis, spontaneous bacterial peritonitis, and hepatic encephalopathy. Antibiotics, especially rifaximin, are the most effective therapies for SIBO, and in addition, studies are being conducted to investigate the efficacy of potential therapies such as prokinetic agents, probiotics, non-selective β-receptor blocker, and liver transplantation.
- Liver Cirrhosis /
- Small Intestinal Bacterial Overgrowth /
- Gastrointestinal Microbiome /
- Therapeutics

HTML全文

参考文献(42)

[1]	DRASAR BS, SHINER M. Studies on the intestinal flora. Ⅱ. Bacterial flora of the small intestine in patients with gastrointestinal disorders[J]. Gut, 1969, 10(10): 812-819. DOI: 10.1136/gut.10.10.812.
[2]	GUO XX, HU N, LIAN XX. Features of intestinal flora imbalance in patients with liver cirrhosis and related driving factors[J]. J Clin Hepatol, 2020, 36(7): 1527-1533. DOI: 10.3969/j.issn.1001-5256.2020.07.016. 郭晓霞, 胡娜, 廉晓晓. 肝硬化患者肠道菌群失调的特征及驱动因子分析[J]. 临床肝胆病杂志, 2020, 36(7): 1527-1533. DOI: 10.3969/j.issn.1001-5256.2020.07.016.
[3]	WIEST R, LAWSON M, GEUKING M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol, 2014, 60(1): 197-209. DOI: 10.1016/j.jhep.2013.07.044.
[4]	SCARPELLINI E, ABENAVOLI L, CASSANO V, et al. The apparent asymmetrical relationship between small bowel bacterial overgrowth, endotoxemia, and liver steatosis and fibrosis in cirrhotic and non-cirrhotic patients: A single-center pilot study[J]. Front Med (Lausanne), 2022, 9: 872428. DOI: 10.3389/fmed.2022.872428.
[5]	GURUSAMY SR, SHAH A, TALLEY NJ, et al. Small intestinal bacterial overgrowth in functional dyspepsia: a systematic review and meta-analysis[J]. Am J Gastroenterol, 2021, 116(5): 935-942. DOI: 10.14309/ajg.0000000000001197.
[6]	GALLOWAY D, MEZOFF E, ZHANG W, et al. Serum unconjugated bile acids and small bowel bacterial overgrowth in pediatric intestinal failure: A pilot study[J]. JPEN J Parenter Enteral Nutr, 2019, 43(2): 263-270. DOI: 10.1002/jpen.1316.
[7]	CORAZZA GR, MENOZZI MG, STROCCHI A, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing[J]. Gastroenterology, 1990, 98(2): 302-309. DOI: 10.1016/0016-5085(90)90818-l.
[8]	REZAIE A, BURESI M, LEMBO A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus[J]. Am J Gastroenterol, 2017, 112(5): 775-784. DOI: 10.1038/ajg.2017.46.
[9]	MADIGAN KE, BUNDY R, WEINBERG RB. Distinctive clinical correlates of small intestinal bacterial overgrowth with methanogens[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.09.035.[Online ahead of print]
[10]	RICHARD N, DESPREZ C, WUESTENBERGHS F, et al. The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth[J]. United European Gastroenterol J, 2021, 9(6): 645-654. DOI: 10.1002/ueg2.12116.
[11]	SHAH A, SHANAHAN E, MACDONALD GA, et al. Systematic review and meta-analysis: prevalence of small intestinal bacterial overgrowth in chronic liver disease[J]. Semin Liver Dis, 2017, 37(4): 388-400. DOI: 10.1055/s-0037-1608832.
[12]	CIRERA I, BAUER TM, NAVASA M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis[J]. J Hepatol, 2001, 34(1): 32-37. DOI: 10.1016/s0168-8278(00)00013-1.
[13]	MIELE L, VALENZA V, LA TORRE G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease[J]. Hepatology, 2009, 49(6): 1877-1887. DOI: 10.1002/hep.22848.
[14]	ZHOU YJ. Gut microbiota and liver cirrhosis[J]. J Prac Hepatol, 2016, 19(2): 139-142. DOI: 10.3969/j.issn.1672-5069.2016.02.004. 周永健. 肠道微生态与肝硬化[J]. 实用肝脏病杂志, 2016, 19(2): 139-142. DOI: 10.3969/j.issn.1672-5069.2016.02.004.
[15]	KHAN A, DING Z, ISHAQ M, et al. Understanding the effects of gut microbiota dysbiosis on nonalcoholic fatty liver disease and the possible probiotics role: recent updates[J]. Int J Biol Sci, 2021, 17(3): 818-833. DOI: 10.7150/ijbs.56214.
[16]	MAN S, YANG L, XIANG H, et al. Antihypertensive and renal protective effect of Shunaoxin pill combined with captopril on spontaneous hypertension rats[J]. Biomed Pharmacother, 2020, 125: 109977. DOI: 10.1016/j.biopha.2020.109977.
[17]	CHEUNG A, TANNA S, ISON MG. Infectious complications in critically ill liver failure patients[J]. Semin Respir Crit Care Med, 2018, 39(5): 578-587. DOI: 10.1055/s-0038-1673657.
[18]	HOLVAST A, KATS-UGURLU G, BODEWES F, et al. Reversal of secondary protein-losing enteropathy after surgical revision of a jejunal Roux-en-Y loop in a patient after liver transplantation[J]. Am J Transplant, 2019, 19(7): 2116-2121. DOI: 10.1111/ajt.15354.
[19]	ABID S, KAMRAN M, ABID A, et al. Minimal hepatic encephalopathy: Effect of H. pylori infection and small intestinal bacterial overgrowth treatment on clinical outcomes[J]. Sci Rep, 2020, 10(1): 10079. DOI: 10.1038/s41598-020-67171-7.
[20]	GHOSH G, JESUDIAN AB. Small intestinal bacterial overgrowth in patients with cirrhosis[J]. J Clin Exp Hepatol, 2019, 9(2): 257-267. DOI: 10.1016/j.jceh.2018.08.006.
[21]	SOUTO PA, MARCOTEGUI AR, ORBEA L, et al. Hepatic encephalopathy: Ever closer to its big bang[J]. World J Gastroenterol, 2016, 22(42): 9251-9256. DOI: 10.3748/wjg.v22.i42.9251.
[22]	ZHANG Y, FENG Y, CAO B, et al. The effect of small intestinal bacterial overgrowth on minimal hepatic encephalopathy in patients with cirrhosis[J]. Arch Med Sci, 2016, 12(3): 592-596. DOI: 10.5114/aoms.2015.55675.
[23]	GUNNARSDOTTIR SA, SADIK R, SHEV S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension[J]. Am J Gastroenterol, 2003, 98(6): 1362-1370. DOI: 10.1111/j.1572-0241.2003.07475.x.
[24]	STEINGERDUR AG, RIADH S, STEVEN S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension[J]. Am J Gastroenterol, 2003, 98(6): 1362-1370. DOI: 10.1016/S0002-9270(03)00250-8.
[25]	MASLENNIKOV R, PAVLOV C, IVASHKIN V. Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis[J]. Hepatol Int, 2018, 12(6): 567-576. DOI: 10.1007/s12072-018-9898-2.
[26]	CAO LT, SUN JY, LI CY, et al. Advances in research on cirrhosis and small intestinal bacterial overgrowth[J]. J Ningxia Med Univ, 2021, 43(8): 870-875. DOI: 10.16050/j.cnki.issn1674-6309. 曹莉婷, 孙瑾瑜, 李初谊, 等. 肝硬化与小肠细菌过度生长的研究进展[J]. 宁夏医科大学学报, 2021, 43(8): 870-875. DOI: 10.16050/j.cnki.issn1674-6309.
[27]	RAMACHANDRAN A, PRABHU R, THOMAS S, et al. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals[J]. Hepatology, 2002, 35(3): 622-629. DOI: 10.1053/jhep.2002.31656.
[28]	JIA FZ. Hepatopathy and intestinal microecology environment[J]. Chin J Pract Int Med, 2006, 26(13): 971-974. DOI: 10.3969/j.issn.1005-2194.2006.13.005. 贾辅忠. 肝病与肠道微生态环境[J]. 中国实用内科学杂志, 2006, 26(13): 971-974. DOI: 10.3969/j.issn.1005-2194.2006.13.005.
[29]	MOUILLOT T, RHYMAN N, GAUTHIER C, et al. Study of small intestinal bacterial overgrowth in a cohort of patients with abdominal symptoms who underwent bariatric surgery[J]. Obes Surg, 2020, 30(6): 2331-2337. DOI: 10.1007/s11695-020-04477-5.
[30]	RAO S, BHAGATWALA J. Small intestinal bacterial overgrowth: clinical features and therapeutic management[J]. Clin Transl Gastroenterol, 2019, 10(10): e00078. DOI: 10.14309/ctg.0000000000000078.
[31]	LIU ZJ, DUAN LP. Advances in research on small intestinal bacterial overgrowth[J]. Chin J Child Health Care, 2017, 25(8): 793-833. DOI: 10.11852/zgetbjzz2017-25-08-11. 刘作静, 段丽萍. 小肠细菌过度生长研究进展[J]. 中国儿童保健杂志, 2017, 25(8): 793-833. DOI: 10.11852/zgetbjzz2017-25-08-11.
[32]	ZENG X, SHENG X, WANG PQ, et al. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis[J]. Hepatol Int, 2021, 15(1): 155-165. DOI: 10.1007/s12072-020-10117-y.
[33]	CHOJNACKI C, POPLAWSKI T, KONRAD P, et al. Serotonin pathway of tryptophan metabolism in small intestinal bacterial overgrowth-A pilot study with patients diagnosed with lactulose hydrogen breath test and treated with rifaximin[J]. J Clin Med, 2021, 10(10): 2065. DOI: 10.3390/jcm10102065.
[34]	ZHUANG X, TIAN Z, LUO M, et al. Short-course rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome[J]. BMC Gastroenterol, 2020, 20(1): 187. DOI: 10.1186/s12876-020-01336-6.
[35]	KANG SH, LEE YB, LEE JH, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy[J]. Aliment Pharmacol Ther, 2017, 46(9): 845-855. DOI: 10.1111/apt.14275.
[36]	FURNARI M, DE ALESSANDRI A, CRESTA F, et al. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin[J]. J Gastroenterol, 2019, 54(3): 261-270. DOI: 10.1007/s00535-018-1509-4.
[37]	FUKUI H. Leaky gut and gut-liver axis in liver cirrhosis: Clinical studies update[J]. Gut Liver, 2021, 15(5): 666-676. DOI: 10.5009/gnl20032.
[38]	NOURI GHARAJALAR S, KAZEMI-DARABADI S, VALINEZHAD LAJIMI H, et al. The roles of lactobacillus acidophilus and pectin in preventing postoperative sepsis and intestinal adaptation in a rat model of short bowel syndrome[J]. Probiotics Antimicrob Proteins, 2021, 13(5): 1355-1362. DOI: 10.1007/s12602-021-09764-w.
[39]	SENZOLO M, CHOLONGITAS E, BURRA P, et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis[J]. Liver Int, 2009, 29(8): 1189-1193. DOI: 10.1111/j.1478-3231.2009.02038.x.
[40]	REIBERGER T, FERLITSCH A, PAYER BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis[J]. J Hepatol, 2013, 58(5): 911-921. DOI: 10.1016/j.jhep.2012.12.011.
[41]	SHI H, MAO L, WANG L, et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol, 2021, 33(1S Suppl 1): e535-e539. DOI: 10.1097/MEG.0000000000002157.
[42]	HAMMER HF, FOX MR, KELLER J, et al. European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus[J]. United European Gastroenterol J, 2022, 10(1): 15-40. DOI: 10.1002/ueg2.12133.